

What is claimed is:

1. A method of treating a sensory neuron related disorder, comprising the step of transdermally applying a pharmaceutically effective amount of Botulinum toxin type A to an affected area of a human exhibiting symptoms of the sensory neuron related disorder.
2. The method of treating a sensory neuron related disorder as set forth in claim 1, including the preliminary step of preparing a topical solution in which Botulinum toxin type A is the active ingredient.
3. The method of treating a sensory neuron related disorder as set forth in claim 2, wherein the step of preparing a topical solution further comprises the steps of:
reconstituting a pharmaceutically effective amount of Botulinum toxin type A with saline; and
mixing the reconstituted Botulinum toxin type A with a suitable base.
4. The method of treating a sensory neuron related disorder as set forth in claim 3, wherein the suitable base includes a pluronic lecithin organogel.
5. The method of treating a sensory neuron related disorder as set forth in claim 1, further comprising the step of providing a transdermal patch in which Botulinum toxin type A is the active ingredient, and wherein the step of transdermally applying the Botulinum toxin type A includes applying said transdermal patch at an affected area of the human.
6. The method of treating a sensory neuron related disorder as set forth in claim 5, wherein the transdermal patch comprises a backing layer, a reservoir layer containing the Botulinum toxin type A, and a release layer.

7. The method of treating a sensory neuron related disorder as set forth in claim 1, wherein the sensory neuron related disorder is migraine.
8. The method of treating a sensory neuron related disorder as set forth in claim 1, wherein the sensory neuron related disorder is diabetic neuropathy.
9. The method of treating a sensory neuron related disorder as set forth in claim 1, wherein the step of transdermally applying the Botulinum toxin type A comprises electrophoresis.
10. An article for the treatment of a sensory neuron related disorder comprising:
 - a backing layer;
 - a reservoir layer containing a pharmaceutically effective amount of Botulinum toxin type A as active ingredient therein; and
 - a release liner.
11. A topical solution for the treatment of a sensory neuron related disorder comprising:
 - a pharmaceutically effective amount of Botulinum toxin type A as active ingredient reconstituted in saline; and
 - a suitable base.
12. The topical solution for the treatment of a sensory neuron related disorder as set forth in claim 11, wherein the base comprises a pluronic lecithin organogel.
13. The topical solution for the treatment of a sensory neuron related disorder as set forth in claim 12, wherein the pluronic lecithin organogel contains a lecithin/isopropyl palmitate solution and a pluronic F127 solution.

14. A method of treating a sensory neuron related disorder, comprising the step of inhibiting the release of neuropeptides by the transdermal application of a pharmaceutically effective amount of Botulinum toxin type A to a human exhibiting symptoms of the sensory neuron related disorder.

15. The method of treating a sensory neuron related disorder as set forth in claim 14, wherein the neuropeptide inhibited is calcitonin gene-related peptide.

16. A method of treating migraine, comprising the steps of:
reconstituting a pharmaceutically effective amount of Botulinum toxin type A with saline;
mixing the reconstituted Botulinum toxin type A with a base including a pluronic lecithin organogel; and
transdermally applying the topical cream to an affected area of a human exhibiting symptoms of migraine.